Login / Signup

Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis.

Behzad AbbasiNathan M ShawJason L LuiNizar HakamBehnam NabavizadehBenjamin N Breyer
Published in: Pharmacoepidemiology and drug safety (2023)
PDE5i use shows disproportionate priapism signals which are higher in young patients.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • peritoneal dialysis
  • prognostic factors
  • patient reported outcomes